Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013460319> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3013460319 endingPage "1601" @default.
- W3013460319 startingPage "1601" @default.
- W3013460319 abstract "Chemotherapy-induced mutations can cause drug resistance in some patients with acute lymphoblastic leukemia (ALL) and thus cause the disease to relapse according to a study in the journal Blood.1 For the study, researchers analyzed 103 patients with relapsed ALL in China. Findings showed that approximately 20% had treatment-related mutations at relapse, some of which were associated with drug resistance. The mutations are uniquely related to the therapy because they are present only in the genomes of patients with relapsed ALL and not in other pediatric or adult cancer genomes according to investigators. After performing whole genome sequencing of the patients’ leukemic cells and normal DNA and conducting targeted deep sequencing of leukemic cells from 16 patients, researchers found relapse-acquired mutations in 12 genes related to drug responses. They also discovered 2 novel mutational patterns or signatures and demonstrated that thiopurines caused 1 of these signatures. In addition, their findings indicated that the mutations led to multidrug resistance. More than half of patients (55%) relapsed 9 to 36 months after their diagnosis but before their treatment was completed. Compared with patients who had relapsed earlier, they had the most relapse-specific mutations in the 12 drug-resistance genes. Investigators say that earlier relapses likely were the result of drug-resistant tumor cells that were present at diagnosis. The later relapses, they added, likely occurred when partially drug-resistant tumor cells present at diagnosis acquired treatment-related mutations. According to the study’s authors, the findings point to the need for both less toxic therapies and more precision medicine approaches, including immunotherapies such as chimeric antigen receptor T cells and bispecific antibodies. Furthermore, drug resistance potentially could be prevented with changes in the dosage or timing of treatment, and screening relapsed patients for drug-resistant mutations may be helpful in the future, the authors say." @default.
- W3013460319 created "2020-04-03" @default.
- W3013460319 creator A5062959891 @default.
- W3013460319 date "2020-03-27" @default.
- W3013460319 modified "2023-09-27" @default.
- W3013460319 title "Chemotherapy can induce relapse in some patients with leukemia" @default.
- W3013460319 cites W2981608667 @default.
- W3013460319 doi "https://doi.org/10.1002/cncr.32862" @default.
- W3013460319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32220079" @default.
- W3013460319 hasPublicationYear "2020" @default.
- W3013460319 type Work @default.
- W3013460319 sameAs 3013460319 @default.
- W3013460319 citedByCount "0" @default.
- W3013460319 crossrefType "journal-article" @default.
- W3013460319 hasAuthorship W3013460319A5062959891 @default.
- W3013460319 hasBestOaLocation W30134603191 @default.
- W3013460319 hasConcept C104317684 @default.
- W3013460319 hasConcept C114851261 @default.
- W3013460319 hasConcept C121608353 @default.
- W3013460319 hasConcept C126322002 @default.
- W3013460319 hasConcept C133936738 @default.
- W3013460319 hasConcept C143998085 @default.
- W3013460319 hasConcept C176944494 @default.
- W3013460319 hasConcept C2776694085 @default.
- W3013460319 hasConcept C2778461978 @default.
- W3013460319 hasConcept C2779134260 @default.
- W3013460319 hasConcept C2780035454 @default.
- W3013460319 hasConcept C501734568 @default.
- W3013460319 hasConcept C54355233 @default.
- W3013460319 hasConcept C71924100 @default.
- W3013460319 hasConcept C86803240 @default.
- W3013460319 hasConcept C98274493 @default.
- W3013460319 hasConceptScore W3013460319C104317684 @default.
- W3013460319 hasConceptScore W3013460319C114851261 @default.
- W3013460319 hasConceptScore W3013460319C121608353 @default.
- W3013460319 hasConceptScore W3013460319C126322002 @default.
- W3013460319 hasConceptScore W3013460319C133936738 @default.
- W3013460319 hasConceptScore W3013460319C143998085 @default.
- W3013460319 hasConceptScore W3013460319C176944494 @default.
- W3013460319 hasConceptScore W3013460319C2776694085 @default.
- W3013460319 hasConceptScore W3013460319C2778461978 @default.
- W3013460319 hasConceptScore W3013460319C2779134260 @default.
- W3013460319 hasConceptScore W3013460319C2780035454 @default.
- W3013460319 hasConceptScore W3013460319C501734568 @default.
- W3013460319 hasConceptScore W3013460319C54355233 @default.
- W3013460319 hasConceptScore W3013460319C71924100 @default.
- W3013460319 hasConceptScore W3013460319C86803240 @default.
- W3013460319 hasConceptScore W3013460319C98274493 @default.
- W3013460319 hasIssue "8" @default.
- W3013460319 hasLocation W30134603191 @default.
- W3013460319 hasLocation W30134603192 @default.
- W3013460319 hasOpenAccess W3013460319 @default.
- W3013460319 hasPrimaryLocation W30134603191 @default.
- W3013460319 hasRelatedWork W2040613549 @default.
- W3013460319 hasRelatedWork W2161840784 @default.
- W3013460319 hasRelatedWork W2175277087 @default.
- W3013460319 hasRelatedWork W2337715549 @default.
- W3013460319 hasRelatedWork W2348371888 @default.
- W3013460319 hasRelatedWork W2374341692 @default.
- W3013460319 hasRelatedWork W2380117124 @default.
- W3013460319 hasRelatedWork W2390745900 @default.
- W3013460319 hasRelatedWork W2438771022 @default.
- W3013460319 hasRelatedWork W2173258789 @default.
- W3013460319 hasVolume "126" @default.
- W3013460319 isParatext "false" @default.
- W3013460319 isRetracted "false" @default.
- W3013460319 magId "3013460319" @default.
- W3013460319 workType "article" @default.